A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis

Thorax

Volumn 71, Issue 2, 2016, Pages 141-147

  Dentice, Ruth L ^a,b   Elkins, Mark R ^a,b   Middleton, Peter G ^c   Bishop, Jennifer R ^c   Wark, Peter A B ^d   Dorahy, Douglas J ^d   Harmer, Christopher J ^b   Hu, Honghua ^b,e   Bye, Peter T P ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d JOHN HUNTER HOSPITAL   (Australia)

^e MACQUARIE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

SALBUTAMOL SULFATE; SODIUM CHLORIDE;

ADOLESCENT; ADULT; ARTICLE; BACTERIAL LOAD; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG TOLERABILITY; DYSPNEA; EXERCISE TOLERANCE; FATIGUE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; LUNG CONGESTION; MAJOR CLINICAL STUDY; MALE; OXYGENATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; STAPHYLOCOCCUS AUREUS; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; FOLLOW UP; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PHYSIOLOGY; TREATMENT OUTCOME; TRENDS; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; CYSTIC FIBROSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; QUALITY OF LIFE; SALINE SOLUTION, HYPERTONIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84958963060     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2014-206716     Document Type: Article

References (32)

1. Boucher RC. Airway surface dehydration in CF: pathogenesis and therapy. Annu Rev Med 2007;58:157-70.
2. Flume PA, Mogayzel PJJ, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009;180:802-8.
3. Liou T, Adler F, FitzSimmons S, et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001;153:345-52.
4. de Boer K, Vandemheen KL, Tullis E, et al. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax 2011;66:680-5.
5. Waters V, Stanojevic S, Atenafu E, et al. Effect of pulmonary exacerbations on long term lung function decline in cystic fibrosis. Eur Respir J 2012;40:61-6.
6. Yi MS, Tsevat J, Wilmott RW, et al. The impact of treatment of pulmonary exacerbations on the health-related quality of life of patients with cystic fibrosis: does hospitalization make a difference? J Pediatr 2004;144:711-18.
7. Tarran R, Grubb BR, Parsons D, et al. The CF salt controversy: in vivo observations and therapeutic approaches. Mol Cell 2001;8:149-58.
8. Robinson M, Hemming AL, Regnis JA, et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 1997;52:900-3.
9. Eng PA, Morton J, Douglass JA, et al. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr Pulmonol 1996;21:77-83.
10. Robinson M, Regnis JA, Bailey DL, et al. Effect of hypertonic saline, amiloride and cough on mucociliary clearance in patients with cystic fibrosis. Am J Respir Crit Care Med 1996;153:1503-9.
11. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-40.
12. Williams HD, Behrends V, Bundy JG, et al. Hypertonic saline therapy in cystic fibrosis: do population shifts caused by the osmotic sensitivity of infecting bacteria explain the effectiveness of this treatment? Frontiers Microbiol 2010;1:120.
13. Havasi V, Hurst CO, Briles TC, et al. Inhibitory effects of hypertonic saline on P. aeruginosa motility. J Cyst Fibros 2008;7:267-9.
14. Behrends V, Ryall B, Wang X, et al. Metabolic profiling of Pseudomonas aeruginosa demonstrates that the anti-sigma factor MucA modulates osmotic stress tolerance. Mol Biosyst 2010;6:562-9.
15. Wark P, McDonald V, Jones AP. Nebulised hypertonic saline for cystic fibrosis. Cochrane Datab Syst Rev 2005;3:CD001506.
16. Dentice R, Elkins M, Middleton P, et al. A randomised controlled trial of the effect of hypertonic saline (HS) inhalation on exacerbation resolution, hospital length of stay and time to relapse in adults with cystic fibrosis. J Cyst Fibros 2013;12(S1):S38.
17. Dentice R, Elkins M, Middleton P, et al. A randomised trial of hypertonic saline nebulisation during hospitalisation for pulmonary exacerbations in adults with cystic fibrosis. Pediatr Pulmonol 2012;S35:257.
18. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994;331:637-42.
19. Wark P, McDonald V. Nebulised hypertonic saline for cystic fibrosis. Cochrane Datab Syst Rev 2009;2:CD001506.
20. Laube B, Sharpless G, Carson K, et al. Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulm Med 2011;11:45.
21. Sood N, Bennett WD, Zeman K, et al. Increasing concentration of inhaled saline with or without amiloride: effect on mucociliary clearance in normal subjects. Am J Respir Crit Care Med 2003;167:158-63.
22. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with Cystic Fibrosis. N Engl J Med 1999;340:23-30.
23. McIlwaine MP, Van Ginderdeuren F, eds. Physiotherapy for people with cystic fibrosis: from infant to adult. 4th edn. International Physiotherapy Group for Cystic Fibrosis, 2009.
24. Elkins MR, Dentice RL, Bye PT. Reliability and repeatability of the MST-25: an extension of the Modified Shuttle Test (MST). Pediatr Pulmonol 2009;44(S32):369, A445.
25. Ware J, Sherbourne C. The MOS 36-item short-form health survey: conceptual framework and item selection. Med Care 1992;30:473-81.
26. Quittner AL, Sweeny S, Watrous M, et al. Translation and linguistic validation of a disease-specific quality of life measure for cystic fibrosis. J Pediatr Psychol 2000;25:403-14.
27. Dentice R, Elkins M, Bye P. Adults with cystic fibrosis prefer hypertonic saline before or during airway clearance techniques: a randomised crossover trial. J Physiother 2012;58:33-40.
28. Sanders DB, Bittner RC, Rosenfeld M, et al. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010;182:627-32.
29. Sanders DB, Hoffman LR, Emerson J, et al. Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol 2010;45:127-34.
30. Sanders DB, Bittner RC, Rosenfeld M, et al. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol 2011;46:393-400.
31. Leonard W, Zobell JT, Ensign R, et al. Retrospective evaluation of appropriate duration of intravenous antibiotic therapy for acute cystic fibrosis exacerbations. Pediatr Pulmonol 2011;36(S34):331.
32. Pezzulo A, Stoltz D, Hornick D, et al. Inhaled hypertonic saline in adults hospitalised for exacerbation of cystic fibrosis lung disease: a retrospective study. BMJ Open 2012;2:e000407.